DekaBank Deutsche Girozentrale
GTBP icon

DekaBank Deutsche Girozentrale’s GT Biopharma GTBP Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,154,867
Closed -$29M – 1418
2024
Q4 		$29M Hold
1,154,867
– – 0.05% 268
2024
Q3 		$35.1M Buy
1,154,867
+176,509
+18% +$422K 0.07% 250
2024
Q2 		$37.8M Buy
+978,358
New +$3.5M 0.07% 231

Other funds holding GTBP

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

DekaBank Deutsche Girozentrale's GTBP Position: Q1 2025 in Review

DekaBank Deutsche Girozentrale sold out of GT Biopharma (GTBP) in Q1 2025, closing a stake of 1,154,867 shares — an estimated $29M sold.

DekaBank Deutsche Girozentrale first reported a position in GTBP in Q2 2024 and held it in 3 quarters. The position peaked at $37.8M in Q2 2024. 20 funds tracked by Wall St. Rank hold GTBP as of Q1 2025.

  • DekaBank Deutsche Girozentrale reported no remaining GT Biopharma position as of Q1 2025 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 1,154,867 GT Biopharma shares in Q1 2025, an estimated $29M.
  • DekaBank Deutsche Girozentrale first reported a position in GT Biopharma in Q2 2024 and held it in 3 quarters.
  • DekaBank Deutsche Girozentrale's GT Biopharma position peaked at $37.8M in Q2 2024.
  • 20 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2025.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2025, filed 30 Apr 2025.